Elicio Therapeutics (ELTX -3.20%), a biotechnology company focused on immunotherapies for cancer, reported its second quarter results on August 7, 2025, for the period ending June 30. The company recorded a net loss per share of $0.66 (GAAP) for the second quarter, less than the expected $(0.69) loss (GAAP). Research and development spending (GAAP) fell from the prior year, while general administration costs increased. No product revenue was reported, as the company remains in the clinical development phase. The quarter’s highlight was a positive independent review allowing its lead pancreatic cancer vaccine trial to proceed as planned. Elicio’s operating spending and cash balance reflected steady management ahead of an important upcoming clinical milestone.
| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change |
|---|---|---|---|---|
| EPS (GAAP) | $(0.66) | $(0.69) | $(0.64) | (3.1% decrease) |
| Revenue (GAAP) | N/A | $0.0 | N/A | N/A |
| R&D Expense | $7.0 million | $8.2 million | (14.6%) | |
| G&A Expense | $3.1 million | $2.7 million | 14.8% | |
| Net Loss | $(10.6 million) | $(7.2 million) | (47.2%) |
Source: Analyst estimates for the quarter provided by FactSet.
Company Overview and Business Model
Elicio Therapeutics operates as a clinical-stage biotechnology company. It develops immunotherapies to help the body’s immune system recognize and attack cancer by targeting specific genetic mutations that drive tumor growth. The company’s core technology, called Amphiphile (AMP), is engineered to direct vaccine components to the lymph nodes, which play a central role in activating immune cells known as T cells.
The company’s main business focus is advancing its AMP platform through clinical trials. Its lead product candidate, ELI-002, is an off-the-shelf vaccine aimed at treating cancers with KRAS mutations. These mutations are commonly found in solid tumors including pancreatic and colorectal cancers. Success depends on showing that AMP-based treatments actually improve patient outcomes in well-designed studies and on securing enough funding to maintain research into further stages of development.
Quarter Highlights and Operational Developments
The company’s major news this quarter was progress in its ELI-002 7P program for pancreatic cancer. In August, a panel of independent experts, known as the Independent Data Monitoring Committee (IDMC), reviewed mid-stage results from the Phase 2 AMPLIFY-7P trial. The IDMC approved the study to continue without changes, citing positive efficacy and safety findings so far. This green light means that Elicio will be able to complete its pivotal analysis later in the year.
Operating costs shifted year-over-year. Research and development spending (GAAP) dropped by $1.2 million, reflecting less manufacturing activity as the ELI-002 clinical program advanced. Meanwhile, general and administrative costs increased by $0.4 million, mainly related to expenses for a financing deal completed in June.
Total operating expenses (GAAP) stood at $10.1 million for the second quarter, lower than the prior year period. The company’s net loss (GAAP) widened to $10.6 million, compared to $7.2 million in the prior year period. Management attributed this mainly to a routine adjustment in the value of outstanding warrants and the recognition of a grant income line.
No revenue was recognized, as is typical for a biotech company that has not yet commercialized a product. Elicio added $10 million in new, non-dilutive financing during the second quarter, extending its cash reserves. This helps cover operations through at least the first quarter of 2026 and gets the company past the critical data readout for its AMPLIFY-7P trial in pancreatic cancer.
Clinical Pipeline and Key Success Factors
ELI-002 is an experimental vaccine for cancers driven by mutated KRAS genes. It is designed to be used in a broad section of patients with pancreatic and colorectal cancer, targeting about a quarter of all solid tumors. The company’s main clinical trial, called AMPLIFY-7P, is testing whether ELI-002 can improve the length of time patients remain free of cancer after initial treatment. Previous data from the AMPLIFY-201 Phase 1 trial, presented at the ESMO Immuno-Oncology Congress 2024, showed a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for patients. These figures are being used to support ongoing development.
Beyond ELI-002, Elicio is working on other preclinical candidates named ELI-007 and ELI-008, which target the BRAF and TP53 gene mutations found in other types of cancer. All these candidates use the same AMP technology, which aims to increase immune response in the lymph nodes. Plans are in place to expand the use of this platform beyond cancer, into areas such as infectious disease and autoimmune disorders. Strategic collaborations are considered important for this next stage, but none were reported during this quarter.
Financial Outlook and Looking Ahead
Management stated that its current cash reserves should support operations through the first quarter of 2026. No new partnership deals or revenue streams were announced. An important clinical milestone is coming up: the next analysis of the AMPLIFY-7P trial will take place in the last quarter of 2025, which could inform plans to start a pivotal Phase 3 trial. The company previously agreed with the U.S. Food and Drug Administration (FDA) on the main features of this future trial.
No formal guidance on future revenue or profits was provided. The primary focus remains advancing its clinical programs and preserving cash while preparing for potential regulatory discussions after the upcoming study results.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
